{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.00","upperLimit":"8.00","value":"6.00"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"}],"units":"Participants"}],"description":"Time to maximum plasma concentration of INCB057643 administered as monotherapy in fed state","dispersionType":"Full Range","groups":[{"description":"Initial cohort dose of INCB057643 monotherapy at the protocol specified starting dose in Part 2 TGA and TGB","id":"OG000","title":"12mg QD INCB057643"}],"paramType":"MEDIAN","populationDescription":"PK evaluable population includes all subjects who received at least 1 dose of study drug and had at least 1 PK sample collected and analyzed","reportingStatus":"POSTED","timeFrame":"C2D1","title":"Part 2-Tmax: Time to Maximum Plasma Concentration of INCB057643","type":"SECONDARY","unitOfMeasure":"hours"}